SCHEMBL5229557

SCHEMBL5229557

COc1ccc(C(N)=O)cc1NC(=O)c1csc(C2CCN(C(=O)c3cc4ccccc4o3)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.46
KDM4E B2RXH2 5/20 0.46
HSD17B10 Q99714 5/20 0.46
ALDH1A1 P00352 5/20 0.46
TSHR P16473 4/20 0.46
NPSR1 Q6W5P4 2/20 0.46
TAAR1 Q96RJ0 1/20 0.45
RAB9A P51151 5/20 0.45
NPC1 O15118 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MIF P14174 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
TP53 P04637 3/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14432776 0.88 TP53 (0.47) HPGDALDH1A1L3MBTL1LMNACYP1A2
SCHEMBL14433142 0.83 ALDH1A1 (0.47) ALDH1A1L3MBTL1LMNACYP1A2TP53
SCHEMBL14432801 0.82 CYP1A2 (0.41) NPC1L3MBTL1LMNACYP1A2TP53
SCHEMBL14432861 0.82 TP53 (0.43) KDM4EALDH1A1SMN1; SMN2L3MBTL1LMNA
SCHEMBL14432816 0.81 KDM4E (0.50) HPGDKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL5232381 0.81 CCR5 (0.40) CYP1A2TP53
SCHEMBL5229698 0.81 TP53 (0.42) CYP1A2TP53
SCHEMBL5227563 0.80 MAPT (0.47) HPGDKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL5262635 0.80 MAPT (0.47) HPGDKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL14432804 0.80 CYP1A2 (0.43) HPGDKDM4EALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581528-B1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS METRIS THERAPEUTICS LTD (GB) 2007-08-01 EP claimed
US-20060135501-A1 Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors DSPI LIMITED (GB) 2006-06-22 US claimed
EP-1581528-A1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS Metris Therapeutics Limited (GB) 2005-10-05 EP claimed
WO-2004058750-A1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS METRIS THERAPEUTICS LIMITED (GB) 2004-07-15 WO claimed
EP-1581528-B1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS METRIS THERAPEUTICS LTD (GB) 2007-08-01 EP disclosed
EP-1581528-B1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS METRIS THERAPEUTICS LTD (GB) 2007-08-01 EP disclosed
US-20060135501-A1 Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors DSPI LIMITED (GB) 2006-06-22 US disclosed
EP-1581528-A1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS Metris Therapeutics Limited (GB) 2005-10-05 EP disclosed
WO-2004058751-A1 PIPERIDINYL-THIAZOLE CARBOXAMIDE DERIVATIVES FOR ALTERING VASCULAR TONE METRIS THERAPEUTICS LIMITED (GB) 2004-07-15 WO disclosed
WO-2004058750-A1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS METRIS THERAPEUTICS LIMITED (GB) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135501-A1 Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors PGF, FLT1, VEGFA HPGD 432/4885KDM4E 3265/4885HSD17B10 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.